17,261 trials
Influenza A Virus, H5N1 Subtype
Primary: Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series — 43; 32; 35; 37 Events
Tick Borne Encephalitis
Primary: Outcome of the Neutralization Test (Number of Subjects With Antibody Response Measured by Neutralization Assay) — 6; 14 Participants — p=<0.001
Lymphoma
Primary: Number of Participants With 1 Year Progression Free Survival — 112; 102; 1; 2 Participants
Von Hippel-Lindau Syndrome
Primary: Tabulation of Adverse Events — 13 adverse events
Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma
Primary: Response Rate — 9; 2 Participants
Atopic Dermatitis
Primary: Change From Baseline in Total Sign Score (TSS) in Target Lesions at Day 15: Crisaborole Ointment 2% Versus Vehicle — 7.7; 7.5; 7.1; 7.4 units on a scale — p=0.0071
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) — 514.6; 512.0 dyn*sec/cm^5 — p=0.0220
Urinary Tract Infection
Primary: Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics. — 2; 14 Participants
Hypoxic-ischemic Encephalopathy · Neonatal Encephalopathy · Birth Asphyxia
Primary: Markers of Organ Function — 10; 6; 9; 12 participants
Non Clear Cell Renal Cell Carcinoma (nccRCC)
Primary: Objective Response Rate (ORR) — 25.8 percentage of participants
Radiation Exposure · Enteral Nutrition
Primary: Time to Duodenal Intubation — 1.6; 4.1 Minutes
Osteoarthritis, Knee
Primary: Change From Baseline in Cartilage Thickness in the Total Femorotibial Joint as Evaluated by Quantitative Magnetic Resonance Imaging (qMRI) at Year 2 — -0.02; -0.01…
Meningococcal Disease · Infections, Meningococcal
Primary: Percentages of Subjects With hSBA ≥ Lower Limit Quantitation (LLQ) Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains.
Sarcoidosis; Antimycobacterial Therapy
Primary: Change in Percent Predicted Absolute Forced Vital Capacity (FVC) in Participants With Pulmonary Sarcoidosis, Comparing Baseline With Performance After Completion of 16…
Small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicities by Cohort in Cycle 1, Part 1 — 2; 1; 1; 0 Participants